Overview

Schizophrenia Sensory Gating Deficit With Quetiapine

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is the use of magnetoencephalography or MEG (a machine that measures magnetic activity in your brain) and electroencephalography or EEG (a technique that measures electrical activity in your brain) to study how sounds are processed in individuals with schizophrenia after three months of taking the antipsychotic medication quetiapine.
Details
Lead Sponsor:
New Mexico VA Healthcare System
Collaborator:
AstraZeneca
Treatments:
Quetiapine Fumarate